Based on the TCGA dataset, the prevalence of FGFR genomic alterations in GC is 5–10%, and FGFR2b overexpression and FGFR2 gene amplification is associated with a poor prognosis in advanced GC. This evidence concerns the gene FGFR2 and gastric cancer.